ALNEV.PA
Neovacs S.A. [ALNEV.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALNEV.PA Stock Summary
Top 10 Correlated ETFs
ALNEV.PA
Top 10 Correlated Stocks
ALNEV.PA
In the News
ALNEV.PA Financial details
Company Rating
Neutral
Market Cap
179.36K
Income
-16.99M
Revenue
66.46K
Book val./share
32.21
Cash/share
4.43
Dividend
-
Dividend %
-
Employees
23
Optionable
No
Shortable
Yes
Earnings
02 Oct 2019
P/E
0
Forward P/E
-
PEG
-
P/S
283.73
P/B
-
P/C
0.08
P/FCF
-0.15
Quick Ratio
1.72
Current Ratio
2.32
Debt / Equity
0.07
LT Debt / Equity
0.03
-
-
EPS (TTM)
-1.61K
EPS next Y
-
EPS next Q
-
EPS this Y
-99.75%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-89.82%
Revenue last 5Y
-62.25%
Revenue Q/Q
-309.4%
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-6%
ROE
-8%
ROC
-0.13%
Gross Margin
-23192%
Oper. Margin
-259983%
Profit Margin
-143143%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0E-4-4.0
52W High
-
52W Low
-
RSI
18
Rel Volume
0.01
Avg Volume
4M
Volume
24.87K
Perf Week
-27.45%
Perf Month
-68.38%
Perf Quarter
123233.33%
Perf Half Y
123233.33%
-
-
-
-
Beta
-868.812
-
-
Volatility
0.07%, 0.25%
Prev Close
12.12%
Price
0.37
Change
0%
ALNEV.PA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 145K | 48.29K | 3.54K | 90.58 | 0.04 | |
| Net income per share | -10.78M | -3.83M | -729.37K | -47.57K | -117.6 | |
| Operating cash flow per share | -13.31M | -4.11M | -670.89K | -39.81K | -147.42 | |
| Free cash flow per share | -13.32M | -4.11M | -695.47K | -41.22K | -152.65 | |
| Cash per share | 1.42M | 659.06K | 1.2M | 132.96K | 223.98 | |
| Book value per share | 2.44M | 1.39M | 1.3M | 176.4K | 1.47K | |
| Tangible book value per share | 2.43M | 1.39M | 1.3M | 176.39K | 1.47K | |
| Share holders equity per share | 2.44M | 1.39M | 1.3M | 176.4K | 1.47K | |
| Interest debt per share | 534.04K | 84.18K | 283.69K | 12.17K | 98.96 | |
| Market cap | 16.24M | 9.14M | 20.35M | 9.95M | 1.01M | |
| Enterprise value | 15.05M | 7.9M | 10.66M | -5.27M | 2.17M | |
| P/E ratio | -1.51 | -1.21 | -3.31 | -0.84 | -0.29 | |
| Price to sales ratio | 112 | 96.09 | 683.16 | 441.6 | 911.76 | |
| POCF ratio | -1.22 | -1.13 | -3.6 | -1 | -0.23 | |
| PFCF ratio | -1.22 | -1.13 | -3.47 | -0.97 | -0.22 | |
| P/B Ratio | 6.66 | 3.34 | 1.85 | 0.23 | 0.02 | |
| PTB ratio | 6.66 | 3.34 | 1.85 | 0.23 | 0.02 | |
| EV to sales | 103.81 | 83.07 | 357.95 | -233.63 | 1.95K | |
| Enterprise value over EBITDA | -1.16 | -0.96 | -3.1 | 0.68 | -0.35 | |
| EV to operating cash flow | -1.13 | -0.98 | -1.89 | 0.53 | -0.49 | |
| EV to free cash flow | -1.13 | -0.98 | -1.82 | 0.51 | -0.47 | |
| Earnings yield | -0.66 | -0.83 | -0.3 | -1.19 | -3.5 | |
| Free cash flow yield | -0.82 | -0.89 | -0.29 | -1.03 | -4.54 | |
| Debt to equity | 0.03 | 0.02 | 0.04 | 0.02 | 0.05 | |
| Debt to assets | 0.01 | 0.01 | 0.03 | 0.02 | 0.05 | |
| Net debt to EBITDA | 0.09 | 0.15 | 2.82 | 1.97 | -0.18 | |
| Current ratio | 1.36 | 1.53 | 5.41 | 7.52 | 1.8 | |
| Interest coverage | -27.65 | -77.37 | -1.75 | -3.92 | -10.97 | |
| Income quality | 1.23 | 1.07 | 0.92 | 0.84 | 1.25 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 63.24 | 53.92 | 53.62 | 180.95 | 0 | |
| Research and developement to revenue | 73.04 | 61.66 | 40.21 | 187.23 | 2.25K | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.04 | 0.04 | 0.04 | |
| Capex to revenue | -0.07 | -0.02 | -6.95 | -15.61 | -141.72 | |
| Capex to depreciation | -0.16 | -0.04 | -3.75 | -3.54 | -1.04 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 24.31M | 10.94M | 4.63M | 434.49K | 1.97K | |
| ROIC | -4.16 | -2.4 | -0.28 | -0.17 | -0.11 | |
| Return on tangible assets | -1.49 | -1 | -0.46 | -0.24 | -0.07 | |
| Graham Net | -3.32M | 408.19K | 1.15M | 119.09K | 101.5 | |
| Working capital | 1.7M | 2.49M | 10.68M | 30.15M | 4.02M | |
| Tangible asset value | 2.43M | 2.74M | 10.98M | 43.9M | 44.23M | |
| Net current asset value | 1.63M | 2.42M | 10.59M | 30.12M | 4.01M | |
| Invested capital | 0.03 | 0.02 | 0.04 | 0.02 | 0.05 | |
| Average receivables | 2.56M | 2.92M | 4.29M | 2.22M | 1.7M | |
| Average payables | 5.25M | 3.58M | 2.52M | 1.3M | 1.62M | |
| Average inventory | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |
| Days sales outstanding | 228.84 | 22.02K | 34.71K | 25.9K | 593.75K | |
| Days payables outstanding | 130.74 | 24.44K | 257.14 | 136.2 | 204.79 | |
| Days of inventory on hand | 0 | 0.01 | 0 | 0 | 0 | |
| Receivables turnover | 1.6 | 0.02 | 0.01 | 0.01 | 0 | |
| Payables turnover | 2.79 | 0.01 | 1.42 | 2.68 | 1.78 | |
| Inventory turnover | 0 | 56.21K | 0 | 3.54M | 0 | |
| ROE | -4.42 | -2.76 | -0.56 | -0.27 | -0.08 | |
| Capex per share | -10.05K | -1.19K | -24.57K | -1.41K | -5.22 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 28.36 | 0 | 0.07 | |
| Net income per share | 0 | 0 | -1.61K | 0 | -3.06 | |
| Operating cash flow per share | 0 | 0 | -1.69K | 0 | -2.42 | |
| Free cash flow per share | 0 | 0 | -1.77K | 0 | -2.46 | |
| Cash per share | 0 | 0 | 18.65K | 0 | 4.43 | |
| Book value per share | 0 | 0 | 26.43K | 0 | 32.21 | |
| Tangible book value per share | 0 | 0 | 26.43K | 0 | 32.2 | |
| Share holders equity per share | 0 | 0 | 26.43K | 0 | 32.21 | |
| Interest debt per share | 0 | 0 | 1.38K | 0 | 3.02 | |
| Market cap | 0 | 0 | 1.75M | 0 | 838.76K | |
| Enterprise value | -28.91M | -15.24M | -8.21M | 1.16M | 596.86K | |
| P/E ratio | 0 | 0 | -0.15 | 0 | -0.05 | |
| Price to sales ratio | 0 | 0 | 34.98 | 0 | 8.19 | |
| POCF ratio | 0 | 0 | -0.59 | 0 | -0.25 | |
| PFCF ratio | 0 | 0 | -0.56 | 0 | -0.24 | |
| P/B Ratio | 0 | 0 | 0.04 | 0 | 0.02 | |
| PTB ratio | 0 | 0 | 0.04 | 0 | 0.02 | |
| EV to sales | -485.25 | 411.72 | -164.25 | -23.75 | 5.83 | |
| Enterprise value over EBITDA | 8.56 | 3.5 | 2.3 | -0.43 | -0.17 | |
| EV to operating cash flow | 13.98 | 1.94 | 2.75 | -0.79 | -0.18 | |
| EV to free cash flow | 13.63 | 1.87 | 2.63 | -0.78 | -0.17 | |
| Earnings yield | 0 | 0 | -1.62 | 0 | -5.11 | |
| Free cash flow yield | 0 | 0 | -1.78 | 0 | -4.1 | |
| Debt to equity | 0.01 | 0.02 | 0.05 | 0.02 | 0.07 | |
| Debt to assets | 0 | 0.02 | 0.05 | 0.02 | 0.06 | |
| Net debt to EBITDA | 8.56 | 3.5 | 2.79 | -0.43 | 0.07 | |
| Current ratio | 20.69 | 15.64 | 7.5 | 2.68 | 1.44 | |
| Interest coverage | 0 | 0 | 0 | 0 | -3.01 | |
| Income quality | 0.65 | 0.9 | 1.05 | 1.2 | 0.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 43.65 | -43.77 | 54.22 | -4.09 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.04 | 0.04 | 0.01 | 0.02 | |
| Capex to revenue | -0.87 | 8.02 | -2.68 | 0.42 | -0.53 | |
| Capex to depreciation | -1.17 | -5.39 | -1.82 | -0.27 | -0.69 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 30.92K | 0 | 47.11 | |
| ROIC | -0.1 | -0.1 | -0.06 | -0.07 | -0.07 | |
| Return on tangible assets | -0.08 | -0.18 | -0.06 | -0.02 | -0.08 | |
| Graham Net | 0 | 0 | 16.71K | 0 | 1.09 | |
| Working capital | 35.67M | 32.55M | 29.96M | 5.68M | 2.59M | |
| Tangible asset value | 35.83M | 43.9M | 46.59M | 50.16M | 45.03M | |
| Net current asset value | 35.49M | 30.12M | 29.96M | 3.94M | 2.51M | |
| Invested capital | 0.01 | 0.02 | 0.05 | 0.02 | 0.07 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 61.99 | -12.86 | 2.87K | -12.19 | 1.5K | |
| Days payables outstanding | 45.12 | 44.05 | 52.04 | 106.66 | 122.98 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.45 | -7 | 0.03 | -7.38 | 0.06 | |
| Payables turnover | 1.99 | 2.04 | 1.73 | 0.84 | 0.73 | |
| Inventory turnover | 1.87M | 2.7M | 0 | 0 | 0 | |
| ROE | -0.09 | -0.2 | -0.06 | -0.02 | -0.1 | |
| Capex per share | 0 | 0 | -76.13 | 0 | -0.04 |
ALNEV.PA Frequently Asked Questions
What is Neovacs S.A. stock symbol ?
Neovacs S.A. is a FR stock and trading under the symbol ALNEV.PA
What is Neovacs S.A. stock quote today ?
Neovacs S.A. stock price is $0.37 today.
Is Neovacs S.A. stock public?
Yes, Neovacs S.A. is a publicly traded company.
Company Profile
- Volume Average 4M
- Market Capitalization 179.36K
- Employee 23
- CEO Mr. Hugo Brugiere M.Sc.
- Headquarters Paris,FR
- IPO Date 2010-04-21
-
Website
https://www.neovacs.com 
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
